WealthCare Asset Management LLC Purchases New Holdings in Exelixis, Inc. $EXEL

WealthCare Asset Management LLC purchased a new position in Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 27,214 shares of the biotechnology company’s stock, valued at approximately $1,590,000. Exelixis makes up about 1.4% of WealthCare Asset Management LLC’s portfolio, making the stock its 20th largest holding.

A number of other large investors have also modified their holdings of the stock. Private Client Services LLC boosted its holdings in Exelixis by 0.7% in the third quarter. Private Client Services LLC now owns 28,539 shares of the biotechnology company’s stock valued at $1,667,000 after purchasing an additional 209 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its holdings in Exelixis by 0.5% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock worth $2,549,000 after purchasing an additional 281 shares during the period. Brindle & Bay Financial Advisors LLC increased its holdings in Exelixis by 8.0% during the 3rd quarter. Brindle & Bay Financial Advisors LLC now owns 4,105 shares of the biotechnology company’s stock worth $240,000 after purchasing an additional 305 shares during the period. Fifth Third Wealth Advisors LLC raised its position in Exelixis by 3.8% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 9,077 shares of the biotechnology company’s stock valued at $389,000 after purchasing an additional 333 shares in the last quarter. Finally, Mather Group LLC. boosted its stake in shares of Exelixis by 124.6% in the 3rd quarter. Mather Group LLC. now owns 757 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 420 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on EXEL shares. Stifel Nicolaus boosted their price objective on Exelixis from $47.00 to $51.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Zacks Research raised shares of Exelixis from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 1st. UBS Group set a $55.00 price target on shares of Exelixis in a research note on Monday, August 3rd. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Friday, September 11th. Finally, Barclays boosted their price target on shares of Exelixis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Exelixis presently has an average rating of “Hold” and an average target price of $51.50.

Insider Transactions at Exelixis

In other Exelixis news, Director Mary Beckerle sold 9,812 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the transaction, the director owned 16,079 shares in the company, valued at $862,799.14. This represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is owned by corporate insiders.

Exelixis Stock Performance

NASDAQ:EXEL opened at $65.11 on Tuesday. Exelixis, Inc. has a 1 year low of $36.00 and a 1 year high of $65.59. The stock has a market cap of $16.13 billion, a P/E ratio of 20.47, a P/E/G ratio of 1.81 and a beta of 0.47. The stock has a 50-day simple moving average of $58.31 and a 200-day simple moving average of $50.48.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.06. The business had revenue of $628.69 million during the quarter, compared to the consensus estimate of $636.40 million. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The company’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 EPS. On average, equities research analysts predict that Exelixis, Inc. will post 3.19 EPS for the current year.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.